HER2 CAR-IMAN / LIfT BioSci - LARVOL DELTA

LIfT BioSciences raises £10m in first close of Series A to advance first-in-class allogeneic innate cell therapy (GlobeNewswire) - "LIfT BioSciences...today announces it has successfully raised £10 million in the first close of a Series A financing with the second close scheduled for Q1 2025. The financing round was supported by new investor the Sijbrandij Foundation and existing investors Lifespan Vision Ventures, Starbloom Capital and Jonathan Milner....The funds raised will be used to advance the Company’s IMANs into clinical trials through a Phase I Investigator Initiated Trial with Galway University."

Financing • Non Small Cell Lung Cancer

LIfT BioSciences reports a substantial increase in cancer killing with the addition of a HER2 targeting CAR to its IMAN cell therapy (GlobeNewswire) - "LIfT BioSciences...today reports a substantially marked increase in cancer killing with the attachment of HER2 CAR to its IMAN cell therapy, using the Company’s second-generation N-LIfT platform...LIfT demonstrated in ex-vivo patient tumoroid models that unmodified IMANs alone were capable of destroying a range of very difficult to treat solid tumours that are resistant to chemotherapy and checkpoint inhibitors, including pancreatic, lung, gastric and rectal....LIfT is now in discussions with biopharma companies to licence its N-LIfT platform to give them access to a whole new type of cell therapy platform for their own CAR assets."

Preclinical • Oncology • Solid Tumor • HER-2

LIfT BioSciences heralds a new era of affordable effective cancer cell therapies simply produced from iPSCs (GlobeNewswire) - "LIfT BioSciences...today announced successful proof-of-concept production of its patented cancer killing alpha neutrophils from induced pluripotent stem cells (iPSCs)...The successful outcome observed using iPSCs will allow the Company to produce even more scalable and cost-effective allogeneic immuno-modulatory alpha neutrophils (IMANs) because iPSCs can be almost infinitely expanded (multiplied) to provide a truly off-the-shelf product that can be used in all cancer patients without an ongoing need for stem cell donors....The Company’s first-generation platform, N-LIfT, which is haemopoietic stem cell (HSC) derived, is already moving into the clinic for its allogeneic HSC derived IMAN product with trials planned to commence in H1 2024."

Clinical data • New trial • Oncology • Solid Tumor